Difference between revisions of "Cladribine (Leustatin)"

Revision as of 18:21, 31 July 2019

General information

Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.^[1]^[2]
Route: IV, SC
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

2/26/1993: Initial FDA approval

Also known as

Generic names: 2-chlorodeoxyadenosine, 2-CdA
Brand names: Leustatin, Litak, Movectro

References

[insert-1] 1.0 ^1.1 Cladribine (Leustatin)) package insert

[2] Cladribine (Leustatin) package insert (locally hosted backup)

[3] Cladribine (Leustatin) patient drug information (Chemocare)

[4] Cladribine (Leustatin) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 8: / Line 8: @@
 ==Diseases for which it is used==
 *[[Acute myeloid leukemia]]
-*[[Chronic lymphocytic leukemia (CLL/SLL)]]
+*[[Chronic lymphocytic leukemia]]
 *[[Hairy cell leukemia]]
 *[[Hypereosinophilic syndrome]]